A new study published in the Clinical Journal of the American Society of Nephrology reveals that majority of the Canadians are supportive of providing financial incentives for deceased kidney donation.
Nearly half of the general public in Canada also find it acceptable for living kidney donation. Studies are now needed to determine whether acceptability of financial incentives translates to more available organs to patients in critical need of a transplant.
Kidney transplantation is the best treatment for patients with kidney failure. Unfortunately, there''s a shortage of kidneys available to those in need of a transplant, and donation rates from both living and deceased donors have remained relatively unchanged over the last decade.
Among the major findings:
- 70% and 40% of respondents found financial incentives to be acceptable for deceased and living donors, respectively.
- 45%, 14%, and 27% of the public, health professionals, and people with or affected by kidney disease, respectively, supported monetary payment as a financial incentive for living donors.
- Overall, reimbursement of funeral expenses for deceased donors and a tax break for living donors were the most acceptable forms of financial incentives.
The authors also examined people''s differences in opinion based on household income. "We did not find evidence that those with lower income would be more likely to donate for financial gain. Though it is not possible to determine through a questionnaire whether a system of financial incentives would exploit those with lower income, the results in our questionnaire did not show any evidence of this," said Dr. Barnieh.
Future research should examine whether financial incentives might increase donations from deceased and living kidney donors.
Study co-authors include Scott Klarenbach, MD, John Gill, MD, and Tim Caulfield, LLM.
Disclosures: The authors reported no financial disclosures
The article, entitled "Attitudes Toward Strategies to Increase Organ Donation: Views of the General Public and Health Professionals," will appear online at http://cjasn.asnjournals.org/ on September 27, 2012, doi: 10.2215/CJN.04100412.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 13,500 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.